Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2009
10/27/2009US7608452 Polynucleotides encoding cytokine receptor zcytor19
10/27/2009US7608409 Screening assay using G-protein coupled receptor protein OT7T175
10/27/2009US7608274 Therapeutic processes and useful compositions therefor
10/27/2009US7608269 Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
10/27/2009US7608257 Using a reovirus and chemotherapeutic agents to treat ras-activated neoplastic cells; proliferative disorders
10/27/2009US7608255 Replication-competent anti-cancer vectors
10/27/2009US7608253 end-capped polyethylene glycol carbamate derivatives useful as water-soluble pro-drugs; controll hydrolytic degradation of hydrogels; conjugate polymer drug for controlled release
10/27/2009CA2466724C Benzamide and heteroarylamide as p2x7 receptor antagonists
10/27/2009CA2454664C Cancer treatment with go6976 and its related compounds
10/27/2009CA2446435C 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
10/27/2009CA2404514C Novel substance having physiological property, method for producing the same and uses thereof
10/27/2009CA2381885C Isomeric fused pyrrolocarbazoles and isoindolones
10/27/2009CA2376355C N-heterocyclic derivatives as nos inhibitors
10/27/2009CA2372085C L-ribo-lna analogues
10/27/2009CA2361174C 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
10/27/2009CA2349529C Pge synthase and methods and means for modulating its activity
10/27/2009CA2341434C Pyrrolobenzodiazepine compounds
10/27/2009CA2338141C Polymer complexes of glucuronoglucanes
10/27/2009CA2319837C Hydroxylation activated drug release
10/27/2009CA2318145C Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
10/24/2009CA2683209A1 Pyrimidinones as casein kinase ii (ck2) modulators
10/24/2009CA2665510A1 Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules for vaccines
10/22/2009WO2009129548A1 Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
10/22/2009WO2009129546A1 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
10/22/2009WO2009129545A1 Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
10/22/2009WO2009129408A2 Compositions and methods for treating pathologic angiogenesis and vascular permeability
10/22/2009WO2009129401A1 Kinase inhibitors
10/22/2009WO2009129361A2 Macrocyclic compounds and methods of making and using thereof
10/22/2009WO2009129260A2 Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
10/22/2009WO2009129259A2 Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
10/22/2009WO2009129246A2 Compositions and methods for preparing and using same
10/22/2009WO2009129208A2 Compositions and methods of inducing endoplasmic reticulum stress reponse
10/22/2009WO2009129191A1 Polymorphs of hydrochloride salt o5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b] indole-7-carboxamideand methods of use therefor
10/22/2009WO2009128936A2 Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
10/22/2009WO2009128919A1 Deuterium bearing analogs of anastrozole as aromatase inhibitors for the treatment of breast cancer
10/22/2009WO2009128917A2 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
10/22/2009WO2009128558A1 Activator for peroxisome proliferator-activated receptor
10/22/2009WO2009128547A1 Gene expression inhibitor selective for matrix metalloproteinase-9 gene
10/22/2009WO2009128523A1 Immunostimulating agent
10/22/2009WO2009128521A1 Cysteine protease inhibitor
10/22/2009WO2009128520A1 Heterocyclic compound having inhibitory activity on p13k
10/22/2009WO2009128481A1 Nitrogenated 5-membered heterocyclic compound
10/22/2009WO2009128273A1 Iontophoresis preparation for treating breast cancer and/or mastitis
10/22/2009WO2009127881A1 Anti-areg/hb-egf antibodies and treatment
10/22/2009WO2009127815A1 Aminoalyl-imidazotetrazines for treatment of cancer
10/22/2009WO2009127615A1 Novel imidazole derivatives having microbiocidal activity
10/22/2009WO2009127612A1 Novel pyrazole derivatives
10/22/2009WO2009127609A1 Spirocyclic derivatives as histone deacetylase inhibitors
10/22/2009WO2009127116A1 13-halo-3,15-dioxy gibberellic acid esters and the preparation methods thereof
10/22/2009WO2009127072A1 Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
10/22/2009WO2009127060A1 Novel lipid formulations for nucleic acid delivery
10/22/2009WO2009127059A1 Complexes of isogranulatimide and granulatimide with a cyclodextrm, formulations and their use for the treatment of cancer
10/22/2009WO2009127046A1 Prostate specific membrane antigen antibodies and antigen binding fragments
10/22/2009WO2009114831A3 Process to produce fibrillar proteins and method of treating using fibrillar proteins
10/22/2009WO2009100218A3 Kruppel-like transcription factor klf4/gklf and uses thereof
10/22/2009WO2009099959A3 Tumor cell expression of neuropilin as a target for cancer therapy
10/22/2009WO2009099650A3 Treatment of bladder diseases with a tlr7 activator
10/22/2009WO2009097113A3 Oxazole and thiazole compounds as b-catenin modulators and uses thereof
10/22/2009WO2009097095A9 Methods for treating hematopoietic malignancies
10/22/2009WO2009088992A3 Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
10/22/2009WO2009077956A3 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM
10/22/2009WO2009046827A3 Use of growth hormone-releasing factor and/or mage-3 antigen (271-279) as therapeutic agents
10/22/2009WO2009043518A3 Use of a combination of cart peptides as a therapeutic agent
10/22/2009WO2009040050A3 Use of calcitonin as anti-angiogenic agent
10/22/2009WO2009040048A3 Use of the c-reactive peptide as a therapeutic agent
10/22/2009WO2009040036A3 Use of a galanin peptide as a therapeutic agent
10/22/2009WO2009039982A3 Use of gip alone or in combination with dynorphin b as a therapeutic agent
10/22/2009WO2009039972A3 Use of muramyl dipeptide (mdp) as a therapeutic agent
10/22/2009WO2009039508A9 Preferential killing of cancer cells and activated human t cells using zno nanoparticles
10/22/2009WO2009033810A3 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection
10/22/2009WO2009013358A3 Polysaccharides grafted by polyamines for the preparation of radiopharmaceutical compositions
10/22/2009WO2009003110A3 Metap-2 inhibitor polϋmersomes for therapeutic administration
10/22/2009WO2008128189A9 Anti-cancer compositions and methods
10/22/2009WO2008099071A8 Monoclonal antibody directed against the human ldl receptor
10/22/2009WO2008032162A8 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
10/22/2009WO2007125210A8 Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
10/22/2009WO2002087504A9 Methods for inhibiting tumor cell proliferation
10/22/2009US20090265798 Desaturase genes and uses thereof
10/22/2009US20090264644 Novel Macrolide Compounds With Antibiotic and Antineoplastic Properties
10/22/2009US20090264526 Natural ligand of G protein coupled receptor RCC356 and uses thereof
10/22/2009US20090264513 Expression vector
10/22/2009US20090264508 Focused Libraries, Functional Profiling, Laser Selex, and Deselex
10/22/2009US20090264506 Delivery of polynucleotide agents to the central nervous system
10/22/2009US20090264502 Compositions and their uses directed to hsp27
10/22/2009US20090264488 Novel solid forms of bendamustine hydrochloride
10/22/2009US20090264487 Hemiasterlin analogs
10/22/2009US20090264485 Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents
10/22/2009US20090264468 Methods for treating a disease in which Rho kinase is involved
10/22/2009US20090264455 Androgen Receptor Modulator Compounds and Methods
10/22/2009US20090264447 Pyrimidine compounds for combating pathogenic fungi and cancer
10/22/2009US20090264439 Combination of a) N--4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
10/22/2009US20090264427 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors
10/22/2009US20090264423 Serine-threonine protein kinase and parp modulators
10/22/2009US20090264422 Method of treating disease states using substituted pyrazole compounds
10/22/2009US20090264421 Methods and Compositions for Treating Cancer
10/22/2009US20090264409 Bicyclic Heterocyclic p-38 Kinase Inhibitors
10/22/2009US20090264406 3-methyl-imidazo[1,2-b]pyridazine derivatives
10/22/2009US20090264399 Heterocyclic janus kinase 3 inhibitors
10/22/2009US20090264398 Method for inducing tumor apoptosis by increasing nitric oxide levels
10/22/2009US20090264396 17Alpha, 21-Dihydroxypregnene esters as antiandrogenic agents
1 ... 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 ... 2211